SaadJ(Sirop)KenderianMD

PubMed

• 75 citations
  Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
  Theodora Anagnostou, Irbaz Bin Riaz, Shahrukh K. Hashmi, Mohammad Hassan Murad, Saad S. Kenderian
  The Lancet. Haematology. 2020-11-01
• 44 citations
  CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
  Mohamad Mohty, Jordan Gautier, Florent Malard, Mahmoud Aljurf, Ali Bazarbachi
  Leukemia. 2019-12-01
• 305 citations
  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
  Saad S. Kenderian, Marco Ruella, Olga Shestova, Michael Klichinsky, Vania Aikawa
  Leukemia. 2015-02-27

Journal Articles

• Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies  
  Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morri..., J Clin Invest, 1/29/2016
• Activity of anti-CD19 Chimeric Antigen Receptor T cells in Combination with Ibrutinib in Mouse Xenografts of Mantle Cell Lymphoma  
  Ruella M, Kenderian SS, Shestove O, Fraietta J, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar O, Milone M, Lacey S, Mato A, Schuster S, Kalo..., Clin Cancer Res, 1/27/2016
• The microbiome and immune regulation after transplantation  
  Tabibian JH, Kenderian SS, Transplantation, 1/11/2016
• Novel therapeutic strategies in acute lymphoblastic leukemia  
  Dias A, Kenderian SS, Westin GF, Litzow MR, Curr Hematol Malig Rep, 1/1/2016
• CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia  
  Kenderian SS, Ruella M, Shestova S, Klichinsky M, Aikawa V, Morrissette J, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S, Leukemia, 1/1/2015
• Chimeric Antigen Receptor T cell Therapy in Hematological Malignancies  
  Kenderian SS, Ruella M, Gill S, Kalos M, Cancer Res, 1/15/2014
• Therapeutic Options for Patients with Lymphoma and Liver Dysfunction or Failure During the Mechlorethamine Shortage  
  Sonbol M, Rana V, Kenderian SS, Finnes H, Witzig T, Leuk Lymphoma, 1/1/2014
• Osteomies in rectal cancer patients: what is their psychological impact?  
  Kenderian SS, Stephens EK, Jatoi A, Eur J Cancer Care, 1/1/2014
• Monosomal Karyotype in Philadelphia Chromosome – Negative Acute Lymphoblastic Leukemia  
  Kenderian SS, Al-Kali A, Gangat N, Letendre L, Hogan W, Litzow M, Patnaik M, Blood Cancer J, 1/1/2013
• Clinical use of selective estrogen receptor modulators and aromatase inhibitors in prevention and adjuvant treatment of breast cancer  
  Sirop S, Ingle J, Goetz M, Translational Endocrinology and Metabolism, 1/1/2013
• Acute Lymphoblastic Leukemia in Adolescents and Young Adults: From Genomics to the Clinic  
  Kenderian SS, Litzow M, Clinical Oncology in Adolescents and Young Adults, 1/1/2013
•  
  Soni M, Wiese D, Korant A, Sirop S, Chakravarty B, Gayar A, Bilchik A, Beutler T, Ratz D, Saha S, Am J Surg, 1/29/2011
• Insulin Like Growth Factor Pathway Targeted Therapy in Breast Cancer  
  Sirop S, Haluska P, Current Breast Cancer Reports, 1/1/2010
• Ultrastaging of sentinel lymph nodes (SLNs) vs non-SLNs in colorectal cancer - Do we need both?  
  Wiese D, Sirop S, Yestrepsky B, Ghanem M, Bassily N, Ng P, Liu W, Quiachon E, Ahsan A, Badin J, Saha S, Am J Surg, 1/1/2010
• Sentinel Node Biopsy for the Individualization of Surgical Strategy for Cure of Early Stage Colon Cancer  
  Cahill R, Bembenek A, Sirop S, Leroy J, Schneider W, Wiese D, Bilchik A, Beutler A, Saha S, Shlag P, Ann Surg Oncol, 1/1/2009
• A Prospective Study of the False Positive Diagnosis for Micrometastic Cells in the Sentinel Lymph Nodes in Colorectal Cancers  
  Wiese D, Saha S, Korant A, Yestrepsky B, Sirop S, Ann Surg Oncol, 1/1/2009
• A Prospective Trial Comparing Sentinel Lymph Node Mapping Using 1% Lymphazurin to 1% Methylene Blye in Gastrointestinal Tumors  
  Soni M, Fritz P, Korant A, Chakravarty B, Iddings D, Sirop S, Saha S, Ann Surg Oncol, 1/1/2009
• Join now to see all

Books/Book Chapters

• Micrometastasis in Colon Cancer after Sentinel Lymph Node Mapping 
  Chapter: From local Invasion to Metastatic Cancer 
  Page 361 - 380Saha S, Sirop S, Iddings D, Wiese D, Bilchik A, Beutler T, Ghanem M, Doan K, Viehl C, Zuber MEditors: Stanley Leogn.2009

Abstracts/Posters

• Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition is Mechanistically Supported By a Novel Direct Interaction of G...
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Saad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia
  Kenderian SS, Ruella M, Shestova O, Klichinsky M, Miriam K, Porter DL, June CH, Gill S, American Society for Blood and Marrow Transplantation, 1/1/2016
• Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity
  Tasian S, Kenderian SS, Shen F, Yong L, Fix W, Kozlowski M, Carroll M, Aplenc R, June CH, Grupp S, Gill S, American Society of Hematology meeting, 1/1/2015
• CD33 specific chimeric antigen receptor T cells as a novel conditioning regimen in AML prior to allogeneic bone marrow transplantation
  Kenderian SS, Ruella M, Shestova S, Klichinsky M, Aikawa V, Morrissette J, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S, American Society for Blood and Marrow Transplantation annual meeting, San Diego, CA, 1/1/2015
• CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
  Kenderian SS, Ruella M, Shestova S, Klichinsky M, Porter DL, Carroll M, June CH, Gill S, Translational Research Cancer Centers Consortium, Seven Springs, PA, 1/1/2015
• Combination of ibrutinib and anti-CD19 chimeric antigen receptor T cells for the treatment of relapsing/refractory mantle cell lymphoma
  Ruella M, Kenderian SS, Fraietta J, Shestova O, Qayyum S, Zhang Q, Liu X, Maus M, Lacey S, Mato A, Schuster S, June C, Wasik M, Gill S, European hematology association annual symposium, Vienna, Austria, 1/1/2015
• CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
  Kenderian SS, Ruella M, Shestova S, Klichinsky M, Aikawa V, Morrissette J, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S, American Association for Cancer Research Annual Meeting, 1/1/2015
• Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma
  Ruella M, Kenderian SS, Shestova O, Chen T, Scholler J, Wasik M, June C, Gill S, American Society of Hematology annual meeting, San Francisco, CA, 1/1/2014
• Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies
  Ruella M, Barrett D, Kenderian SS, Shestova O, Hofmann T, Scholler J, Lacey S, Melenhorst J, Nazimuddin F, Kalos M, Porter DL, June CH, Grupp S, Gill S, American Society of Hematology annual meeting, San Francisco, CA, 1/1/2014
• Salvage Autologous Stem Cell Transplantation for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Single Institution Experience
  Sirop S, Habermann T, Macon W, Ristow K, Ansell S, Colgan J, Johnston P, Markovic S, Micallef I, Thompson C, Porrata L, Martenson J, Witzig T, Nowakowski G, Inwards D, Bone Marrow Transplantation Tandem Meeting, Salt Lake City, UT, 1/1/2013
• A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes
  Kenderian SS, Litzow MR, Al-Kali A, Gastineau DA, Hashmi SK, Hogan WJ, Patnaik MM, American Society of Hematology annual meeting, New Orleans, LA, 1/1/2013
• Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and ...
  Kenderian SS, Sharma R, Patnaik MM, Call T, Hashmi SK, Kay NE, Ding W, Litzow MR, Rabe KG, Hogan WJ, Shanafelt TD, American Society of Hematology annual meeting, New Orleans, LA, 1/1/2013
• Clinical Spectrum and Outcomes of Patients with Inherited Bone Marrow Failure Syndromes: A Mayo Clinic Series of 55 Patients
  Kenderian SS, Litzow MR, Gastineau DA, Letendre L, Khan SP, Rodriguez V, Gourde J, Hogan WJ, Abraham RS, Patnaik MM, European Hematology 17th Congress, 1/1/2013
• Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Singl...
  Sirop S, Habermann T, Macon W, Ristow K, Ansell S, Colgan J, Johnston P, Inwards D, Markovic S, Micallef I, Thompson C, Porrata L, Martenson J, Witzig T, Nowakowski G, 54th American Society of Hematology Annual Meeting, Atlanta, GA, 1/1/2013
• Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
  Sirop S, Al-Kali A, Begna K, Gangat N, Letendre L, Porrata L, Hogan W, Litzow M, Patnaik M, 54th American Society of Hematology Annual Meeting, Atlanta, GA, 1/1/2013
• Join now to see all

Lectures

• Preclinical Modeling of CART Cells and Combination Immunotherapy 
  San Francisco, CA - 1/1/2017
• Chimeric antigen receptor T cell therapy: where are we now? 
  Rochester, MN - 1/1/2016
• Chimeric Antigen Receptor T Cell Therapy: Building Smarter CARs 
  Rochester, MN - 1/1/2016
• Preclinical modeling of human CART cells in hematological malignancies 
  Boston, MA - 1/1/2016
• Checkpoint inhibitors in hematology 
  Rome, Italy - 1/1/2016
• CART cell therapy: Beyond CD19 
  Rome, Italy - 1/1/2016
• Checkpoint inhibitors in hematology and Bone Marrow Transplantation 
  Minneapolis, MN - 1/1/2016
• CART cell therapy in the context of stem cell transplantation 
  Minneapolis, MN - 1/1/2016
• Enhancing the therapeutic index of CART cell therapy 
  Philadelphia, PA - 1/1/2015
• CART cell therapy: An alternative or a supplement to BMT? 
  Rochester, MN - 1/1/2015
• CART cell Therapy in Hematological Malignancies 
  Chicago, IL - 1/1/2015
• Evolving therapies in allogeneic stem cell transplantation 
  Yerevan, Armenia - 1/1/2015
• Chimeric antigen receptor T cell therapy in AML 
  Philadelphia, PA - 1/1/2015
• Novel Cellular Conditioning Regimens in BMT 
  1/1/2015
• CD33 directed chimeric antigen receptor T cell therapy in AML 
  Philadelphia, PA - 1/1/2014
• Trainee Research Update 
  Rochester, MN - 1/1/2013
• Paroxysmal Nocturnal Hemoglobinuria 
  Rochester, MN - 1/1/2013
• Cancer of Unknown Origin 
  Rochester, MN - 1/1/2012
• Cutaneous T-cell Lymphoma 
  Rochester, MN - 1/1/2012
• Hemophagocytic Lymphohistiocytosis 
  Rochester, MN - 1/1/2012
• Mast Cell Diseases 
  Rochester, MN - 1/1/2012
• Introduction to Chemotherapy 
  Rochester, MN - 1/1/2012
• Chemotherapy 101 
  Rochester, MN - 1/1/2012
• Updates in Early Stage Hodgkin Disease 
  Rochester, MN - 1/1/2012
• DNA Repair Pathways 
  Rochester, MN - 1/1/2012
• Join now to see all